LabQ 2026 Clinical Laboratory: Molecular Pathology Faculty/Authors
Aniruddha Mundhada, MD Department of Lymphoma/Myeloma The University of Texas MD Anderson Cancer CenterHouston, Texas Shailendra Mundhada, MD, MS Director Dhruv Pathology & Molecular Diagnostic Lab Nagpur, India
CMLE Credit: 2.0Estimated Completion Time: 2 hour
Format: Online Educational Activity and Post Exam
Instructions
To claim CMLE credit for the exercise, do the following:
Faculty DisclosuresThe faculty have no relevant financial relationships with commercial interests to disclose.
Technical Considerations
Release Date: 3/31/2026 Review Date:Expiration Date: 12/31/2028
explain the biological and clinical significance of FLT3 mutations in acute myeloid leukemia (AML), including their role in leukemogenesis, relapse, and poor prognosis;
describe molecular techniques used to detect FLT3 mutations, including polymerase chain reaction (PCR), next-generation sequencing (NGS), and digital droplet PCR;
evaluate the clinical implications of FLT3 mutations, focusing on their prognostic value and how they inform therapeutic decision making;
identify targeted treatment options for patients with FLT3-mutated AML, particularly FLT3 inhibitors such as midostaurin, and their impact on outcomes;
recognize the challenges associated with FLT3 mutation testing, including mutation heterogeneity, assay sensitivity, and lack of standardization; and
understand the role of FLT3 mutation testing in AML management, particularly in stratifying prognosis and selecting appropriate targeted therapies.